Evidence map›Paper›PMID 39079724›Full record

ArticleRespiratory care2024

Feasibility of Delivering 5-Day Normobaric Hypoxia Breathing in a Hospital Setting.

Lorenzo Berra, Kyle J Medeiros, Francesco Marrazzo, Sarvagna Patel, David Imber, Emanuele Rezoagli, Binglan Yu, Abraham Sonny, Edward A Bittner, Daniel Fisher and 7 more

Abstract read
In one paragraph

Article in Respiratory care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Hypoxia as a medicine.Science translational medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lorenzo BerraDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. lberra@mgh.harvard.edu.
Kyle J MedeirosDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Francesco MarrazzoDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Sarvagna PatelDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
David ImberDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Emanuele RezoagliDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Binglan YuDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Abraham SonnyDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Edward A BittnerDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Daniel FisherDepartment of Respiratory Care, Massachusetts General Hospital, Boston, Massachusetts.
Daniel ChipmanDepartment of Respiratory Care, Massachusetts General Hospital, Boston, Massachusetts.
Rohit SharmaHarvard Medical School, Boston, Massachusetts. Department of Systems Biology, Massachusetts General Hospital, Boston, Massachusetts. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Hardik ShahHarvard Medical School, Boston, Massachusetts. Department of Systems Biology, Massachusetts General Hospital, Boston, Massachusetts. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Metabolomics Platform, Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.
Brianna E GrayTranslational and Clinical Research Centers, Massachusetts General Hospital, Boston, Massachusetts.
N Stuart HarrisHarvard Medical School, Boston, Massachusetts. Division of Wilderness Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Fumito IchinoseDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Vamsi K MoothaHarvard Medical School, Boston, Massachusetts. Department of Systems Biology, Massachusetts General Hospital, Boston, Massachusetts. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBeneficial effects of breathing at [Formula: see text] < 0.21 on disease outcomes have been reported in previous preclinical and clinical studies. However, the safety and intra-hospital feasibility of breathing hypoxic gas for 5 d have not been established. In this study, we examined the physiologic effects of breathing a gas mixture with [Formula: see text] as low as 0.11 in 5 healthy volunteers.

methodsAll 5 subjects completed the study, spending 5 consecutive days in a hypoxic tent, where the ambient oxygen level was lowered in a stepwise manner over 5 d, from [Formula: see text] of 0.16 on the first day to [Formula: see text] of 0.11 on the fifth day of the study. All the subjects returned to an environment at room air on the sixth day. The subjects' [Formula: see text], heart rate, and breathing frequency were continuously recorded, along with daily blood sampling, neurologic evaluations, transthoracic echocardiography, and mental status assessments.

resultsBreathing hypoxia concentration dependently caused profound physiologic changes, including decreased [Formula: see text] and increased heart rate. At [Formula: see text] of 0.14, the mean [Formula: see text] was 92%; at [Formula: see text] of 0.13, the mean [Formula: see text] was 93%; at [Formula: see text] of 0.12, the mean [Formula: see text] was 88%; at [Formula: see text] of 0.11, the mean [Formula: see text] was 85%; and, finally, at an [Formula: see text] of 0.21, the mean [Formula: see text] was 98%. These changes were accompanied by increased erythropoietin levels and reticulocyte counts in blood. All 5 subjects concluded the study with no adverse events. No subjects exhibited signs of mental status changes or pulmonary hypertension.

conclusionsResults of the current physiologic study suggests that, within a hospital setting, delivering [Formula: see text] as low as 0.11 is feasible and safe in healthy subjects, and provides the foundation for future studies in which therapeutic effects of hypoxia breathing are tested.

Indexed as

Feasibility StudiesHeart RateHypoxiaAdultFemaleHealthy VolunteersHumansMaleOxygenOxygen Inhalation TherapyRespirationRespiratory RateOxygenhigh-altitudehypoxemiahypoxiahypoxia-inducible factorpulmonary hypertension

Identifiers

PMID39079724
PMCPMC11549621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.